Results of New Analysis Support Use of NanoString Technologies Inc.’s Prosigna Assay to Help Identify Node-Positive Early-Stage Breast Cancer Patients at Low Risk of Recurrence
6/3/2013 1:17:59 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SEATTLE & CHICAGO--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination (ATAC) studies. The results indicated that NanoString’s Prosigna Breast Cancer Assay can be used to help identify node-positive early-stage breast cancer patients who are at low risk of recurrence. These data were presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology (ASCO) meeting on Sunday, June 2.
Help employers find you! Check out all the jobs and post your resume.
comments powered by